Home
About Opexa
About Opexa
Management Team
Board of Directors
Scientific Advisory Board
Facility
Contact Us
Tcelna®
Tcelna® Description
TERMS Phase 2b Overview
MS Overview
Publications
OPX-212
OPX-212 Description
Neuromyelitis Optica
Clinical Trials
Abili-T Clinical Study for Secondary Progressive Multiple Sclerosis Overview
ImmForm® Clinical Management Tool
Technology
T-cell Platform
Opexa cGMP Manufacturing
Pipeline
News & Resources
Multimedia
Press Releases
Webcasts
Publications
Conference & Meeting Presentations
Investor Relations
Why Invest
Press Releases
Events & Presentations
Stock Information
SEC Filings
Financial Reports
Corporate Governance
Analyst Coverage
Investor FAQs
Careers
Working at Opexa
Open Positions
How to Apply
Living in The Woodlands
Contact Us
Contact Us
Precision Immunotherapy™
Home
/
Investor Relations
/
Press Releases
Investor Relations
Why Invest
Press Releases
Events & Presentations
Stock Information
SEC Filings
Financial Reports
Corporate Governance
Analyst Coverage
Investor FAQs
Why Invest
Press Releases
Events & Presentations
Stock Information
SEC Filings
Financial Reports
Corporate Governance
Analyst Coverage
Investor FAQs
Quick Links
Financial Reports
FAQs
Contact IR
Email Alerts
Email Address
*
Mailing Lists
*
Releases
SEC Filings
Presentation
Events
Enter the code shown above.
Unsubscribe from email alerts
Normal
Press Releases
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
07/03/2022
Acer Therapeutics and Opexa Therapeutics Sign Merger Agreement
05/12/2021
Opexa Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
02/01/2022
Opexa Facility Becomes Foundation for Contract Manufacturing and Development Organization for Cellular Therapies
© 2017 Opexa Therapeutics, Inc. All Rights Reserved.
Privacy Policy
Terms of Use
Powered By Q4 Inc.
4.5.0.5